

## Sanifit highlights publication of “50 Key Questions on Calciphylaxis”

**Palma, Spain and San Diego, USA, 21 November, 2018** – Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, is pleased to note the publication of ‘50 Key Questions on Calciphylaxis in Chronic Kidney Disease’ by Dr José Vicente Torregrosa and Dr David Cucchiari, the printing of which was sponsored by Sanifit.

The book, which was recently presented in Madrid during the IX Ibero-American Congress of Nephrology, provides a significant contribution to the body of knowledge on calciphylaxis. It covers the rare disease’s history, the current medical understanding of the condition, and the latest means of diagnosing and managing the disease. As well as increasing physicians’ knowledge of the condition and aiding professional medical training, the book highlights the need for more research, given the fact that the condition has no approved therapies.

Calciphylaxis is the most severe form of cardiovascular calcification, typically affecting end-stage renal disease patients. The condition is characterized by rapid-onset vascular calcification of the small peripheral vessels as well as painful necrotic skin ulcers. It has high morbidity and mortality rates with a 1-year mortality rate of approximately 55%. There are an estimated 30,000 patients worldwide, though this is thought to be an underdiagnosed condition because approved treatments are unavailable and the fact that knowledge about calciphylaxis is not widespread.

**Joan Perelló, PhD, CEO and co-founder of Sanifit, said:** “Sanifit is pleased to be supporting the publication of this important book on calciphylaxis, a rare condition with few treatment options and significant unmet need. We hope it will prove to be a valuable contribution to the medical literature on calciphylaxis as we work towards providing an effective treatment option for this underserved disease area.”

**Laboratoris SANIFIT S.L.**

**Sanifit Inc.**

Phone: +34 971 439 925

PARC BIT. Europa Building. 2<sup>nd</sup> floor | 07121 Palma. Spain

Phone: +1 858 535 48 44

3655 Nobel Drive Suite #540 | CA 92122 San Diego, USA

info@sanifit.com    www.sanifit.com



## For media enquiries:

### Consilium Strategic Communications

Julia Wilson, Chris Welsh

Tel: +44 (0) 20 3709 5700

Email: [sanifit@consilium-comms.com](mailto:sanifit@consilium-comms.com)

### About the authors

**Dr José Vicente Torregrosa**, a nephrology specialist, works in the Nephrology and Kidney Transplantation Department at the Hospital Clinic, University of Barcelona, Spain. His research interests include calciphylaxis, transplant surgery and kidney transplantation. He has published and authored many articles related to these areas and is considered one of the key opinion leaders in calciphylaxis. Dr Torregrosa is leading the Spanish involvement in EuCaINET, the European Calciphylaxis Registry, which is coordinating the efforts of 7 European countries (Belgium, France, Germany, Italy, Spain, The Netherlands and Portugal) in researching the condition.

**Dr David Cucchiari** is a nephrologist and works with Dr Torregrosa in the Hospital Clinic, University of Barcelona, Spain. He previously specialized in nephrology at the University of Milan.

### About SNF472

SNF472 is an intravenous formulation of myo-inositol hexaphosphate with a novel mechanism of action for the treatment of haemodialysis patients with cardiovascular diseases linked to calcification. SNF472 is being developed for two indications: calciphylaxis and cardiovascular disease in end stage renal disease (CV-ESRD) patients undergoing dialysis. SNF472 has orphan drug status for the treatment of calciphylaxis from both the EMA and FDA. SNF472 selectively blocks the progression of pathological cardiovascular calcification and poses an innovative solution for these unmet medical needs.

### About Sanifit

Sanifit is a biopharmaceutical company focused on calcification disorders. The company started operations 2007 after spinning off from the University of the Balearic Islands. It expanded its activities in the USA in 2016 with the incorporation of a subsidiary with offices in San Diego. The company's lead compound, SNF472, has successfully completed a Phase 2 proof of concept study in calciphylaxis, with a Phase 3 pivotal study planned to initiate in H1 2019. The company is also investigating SNF472 in a Phase 2b study in CV-ESRD, with results expected in Q4 2019. Sanifit has raised more than \$50M, including a series C funding of \$41.3M (€36.6M) in mid-2015.

For more information please visit [www.sanifit.com](http://www.sanifit.com)

**Laboratoris SANIFIT S.L.**

**Sanifit Inc.**

Phone: +34 971 439 925

PARC BIT. Europa Building. 2<sup>nd</sup> floor | 07121 Palma. Spain

Phone: +1 858 535 48 44

3655 Nobel Drive Suite #540 | CA 92122 San Diego, USA

[info@sanifit.com](mailto:info@sanifit.com) [www.sanifit.com](http://www.sanifit.com)

